Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    "Hyperlipoproteinemia type 3"
Hide Display Options

Display Options

Study Details
Participant Details
Rank Status Study
1 Recruiting DARK STUDY "DysbetalipoproteinemiA and atheRoma Risk"
Condition: Dysbetalipoproteinemia
2 Completed Type III Dysbetalipoproteinemia
Condition: Hyperlipoproteinemia Type III
Interventions: Drug: Rosuvastatin;   Drug: rosuvastatin;   Drug: pravastatin
3 Terminated Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.
Condition: Hyperlipoproteinemia Type III
Interventions: Drug: torcetrapib/atorvastatin;   Drug: atorvastatin;   Drug: fenofibrate

Indicates status has not been verified in more than two years